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A variety of paracrine signals create networks within the myocardium and mediate
intercellular communications. Indeed, paracrine stimulation of the endogenous
regenerative program of the heart, mainly based on resident cardiac progenitor cell
(CPC) activation together with cardiomyocyte proliferation, has become increasingly
relevant for future cardiac medicine. In the last years, it has been shown that extracellular
vesicles (EV), including exosomes (Ex), are powerful conveyors of relevant biological
effects. EV have been proposed not only as promising therapeutic tool for triggering
cardiac regeneration and improving repair, but also as means of better understanding
the physiological and pathological relationships between specific cardiac components,
including cardiomyocytes and fibroblasts. Actually, EV from different kinds of exogenous
stem cells have been shown to mediate beneficial effects on the injured myocardium.
Moreover, endogenous cells, like CPC can instruct cardiovascular cell types, including
cardiomyocytes, while cardiac stromal cells, especially fibroblasts, secrete EV that
modulate relevant aspects of cardiomyocyte biology, such as hypertrophy and
electrophysiological properties. Finally, cardiomyocytes too may release EV influencing
the function of other cardiac cell types. Therefore, EV-based crosstalk is thought to be
important in both physiology and pathology, being involved in the responses of the heart
to noxious stimuli. In this review we will discuss the role of EV in both regulating cardiac
homeostasis and driving heart regeneration. In particular, we will address their role in: (i)
providing cardio-protection and enhancing cardiac repair mechanisms; (ii) CPC biology;
and (iii) influencing adult cardiomyocyte behavior.
Keywords: paracrine effect, stem cell-extracellular vesicles, cardiac progenitor cell, cardiomyocyte, fibroblast,
exosome
Abbreviations: AF, amniotic fluid; ANG1, angiopoietin 1; ANG2, angiopoietin 2; ATMP, advanced therapy medicinal
product; BM, bone marrow; CDC, cardiosphere-derived progenitor cells; CPC, cardiac progenitor cell; CS, cardiospheres;
EMMPRIN, extracellular matrix metalloproteinase inducer; EPDC, epicardium-derived progenitor cells; ERK, extracellular
signal–regulated kinase; ESC, embryonic stem cells; EV, extracellular vesicles; Ex, exosomes; Fib, fibroblasts; HF, heart failure;
HIF, hypoxia inducible factor; HSP60, heat shock protein 60; I/R, ischemia/reperfusion; IC, intra-coronary; IM, intra-
myocardial; iPSC, induced pluripotent stem cells; Lin-, lineage-negative; LV, left ventricle; MeCP2, Methyl-CpG binding
protein 2; MI, myocardial infarction; miRNA, microRNA; MMP9, matrix metallopeptidase 9; mRNA, messenger RNA; MSC,
mesenchymal stromal cells; MV, microvesicles; nSMase2, neutral sphingomyelinase 2; PAPP-A, pregnancy-associated plasma
protein-A; ROS, reactive oxygen species; UC, umbilical cord; VEGF, vascular endothelial growth factor; WJ, Wharton’s jelly.
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INTRODUCTION
Full cardiac regeneration is well-established in lower vertebrates
including amphibians and the teleost fish; in the zebrafish heart,
responsive reactivation of resident cardiomyocyte proliferation
can occur following severe myocardial injury, such as apex
resection, with almost total reconstitution of viable tissue over
a transient scar (Lepilina et al., 2006; Kikuchi et al., 2010;
Zhao et al., 2014; González-Rosa et al., 2017). On the contrary,
the adult mammalian heart cannot withstand critical damage,
as endowed with poor wound healing response when facing
prolonged ischemia. Indeed, the heart responds to an ischemic
injury – such as the occlusion of a coronary artery causing
the death of a consistent amount of cardiomyocytes – by
promptly triggering an inflammatory response with activation of
myofibroblasts, which rapidly lay down a collagen-enriched scar
tissue to compensate the cardiomyocyte loss. Such scar sustains
mechanical strength and prevents ventricular rupture thereby
avoiding sudden death. Despite this mechanism represents an
emergency plan, it has detrimental consequences in the long
term, including LV maladaptive remodeling with disruption of
cardiac function by ventricular dilatation, scar thinning, and
interstitial fibrosis, overall leading to HF (Pfeffer and Braunwald,
1990; Jameel and Zhang, 2009). Therefore, the emergency
wound healing program can turn into defective repair, which is
worsened by absence of efficient myocardial renewal and de novo
cardiomyocyte restitution.
Restoration of both cardiac structure and function following
injury, disease or aging represents the holy grail of modern
medicine, yet current therapies can only delay progression
of HF. In recent years, several preclinical and clinical efforts
have focused on stem cell-based therapies, including different
cell sources (i.e., BM- and adipose derived-MSC; fetal and
perinatal progenitors, etc.) on the assumption that cells
transplanted into the heart could give rise to new viable and
functional cardiomyocytes and cardiovascular components via
direct trans-differentiation. Despite initial high expectations,
multiple independent lines of investigation have demonstrated
that injected stem cells showed very low engraftment potential,
poor survival and in most cases almost complete failure to
acquire a mature cardiomyocyte phenotype, yet they contributed
to improve cardiac function, mostly via local release of paracrine
trophic factors. Indeed, accumulating evidence indicates that
stem cells can prime the injured heart via paracrine effects,
rather than undergoing de novo differentiation, as confirmed by
the administration of their conditioned medium that contains
all the secreted factors and showed equivalent beneficial results
(Gnecchi et al., 2006). Thus, stem cell-derived paracrine
modulation of cardiac tissue has recently emerged as a promising
strategy for enhancing cardiac repair up to regeneration, with
growing interest toward the functional profiling of the stem cell
“secretome,” as the whole of growth factors, chemo-attractant
molecules and EV produced by paracrine secretion.
In such scenario, much attention has been recently raised
toward the strategic role of stem cell-EV as immunologically
inert vehicles of regenerative activity and exerting pivotal
function in cell-to-cell communication (Barile et al., 2014;
Ibrahim et al., 2014). EV are a heterogeneous population of
membrane-bound vesicles, including nano-sized exosomes (Ex)
and micro-scaled shedding MV (Madonna et al., 2016; Sluijter
et al., 2018). They contain proteins, bioactive lipids, mRNAs,
and miRNAs molecules with relevant paracrine potential (Barile
et al., 2014; Ibrahim et al., 2014). Notably, within the EV
population, growing interest has been specifically dedicated to
the exosome fraction; Ex represent a specific subpopulation of
very small EV (ranging in size from 30 up to 150 nm), which are
products of the endo-lysosomal pathway and have been described
to be functional mediators of regenerative modulatory factors
(Fierabracci et al., 2015; Radosinska and Bartekova, 2017). As
such, EV and Ex have been increasingly analyzed in preclinical
research, including the field of cancer and cardiac disease (Barile
and Vassalli, 2017).
When addressing cardiac regeneration, two important aspects
must be considered as well. First, recent independent studies have
revealed that the heart does retain an endogenous regeneration
capability, although very limited. Part of this potential is based
on CPC activation. CPC are resident cells with stem/progenitor
features mainly involved in cardiogenesis during embryonic
development and participating in cardiac homeostasis and
repair to some extent during adulthood. CPC represent a very
heterogenous cell population as described so far, with putative
tissue-specific cardiovascular and cardiomyogenic potential and
significant paracrine activity, overall supporting cardiac function
following injury (Bollini et al., 2011; Madonna et al., 2016).
Their discovery has overturned the view of the heart as a non-
regenerative organ; however, endogenous repair by CPC remains
inefficient when facing severe pathological situations, unless they
are activated by proper stimulation (Bollini et al., 2011; Laflamme
and Murry, 2011). They represent a very appealing endogenous
therapeutic target to sustain heart regeneration from within the
cardiac tissue, therefore comprehensive characterization of CPC-
EV and their biological activity has been lately gaining growing
attention.
Likewise, the long-held view that mammalian cardiomyocytes
are quiescent has been recently dismissed, although the number
of mitotic cardiomyocytes drops precipitously within the first
week of life. Thereafter, cardiomyocyte renewal rate remains
at 0.5–1% per year in adult humans (Senyo et al., 2013).
Despite being clearly insufficient to offset the loss of billion
cardiomyocytes following myocardial infarct, a key question
is whether this rate of proliferation can be therapeutically
enhanced. Notably, it has been shown that in the neonatal mouse
heart full regeneration following injury can be underpinned
by active proliferation of existing mononuclear cardiomyocytes;
unfortunately, this mechanism is transient, being lost after
the first week of birth (P7), with transition from complete
regeneration to scarring/fibrosis (Porrello et al., 2011).
Thus, the current cardiac regenerative dogma is based
on synergistically optimizing cardiac repair, while also
efficiently triggering both endogenous CPC reactivation
and resident cardiomyocyte renewal, via paracrine effects. In this
scenario, extensive comprehension of EV-mediated intercellular
communication might offer meaningful insights for a future
working strategy in translational medicine. In this review, we
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will critically examine the more relevant recent findings related
to stem cell-EV biology for cardiac repair and regeneration,
while also discussing the paracrine contribution of endogenous
CPC and the emerging role of resident cardiomyocyte and
the surrounding cardiac stromal cell secretory potential in
modulating the tissue microenvironment via EV/Ex interaction.
STEM CELL-EV FOR FUTURE CARDIAC
PARACRINE THERAPY
Stem Cell Biology 2.0: From the Genome
to the Secretome
Within the (stem) cell-based therapy scenario, adult MSC
have been the most investigated cell type in preclinical and
clinical studies of cardiac repair, in either autologous as well
as allogeneic setting. Despite their poor differentiating and
engrafting potential, MSC are being considered a promising
therapeutic source due to their remarkable cardioprotective, pro-
angiogenic and anti-inflammatory paracrine potential. Indeed, in
2006 Gnecchi et al. published a pivotal study demonstrating that
Akt-overexpressing MSC produced a cardioactive secretome by
conditioning their culture medium, which exerted remarkable
beneficial cardioprotective effect when administered to a
preclinical rodent model of acute MI (Gnecchi et al., 2006).
Since then, many independent studies confirmed the favorable
paracrine effect on injured myocardium of different MSC sources.
Transplanted MSC have been shown to instruct the host cardiac
tissue by creating a responsive microenvironment, which is
regulated by local concentration of secreted paracrine factors
(Hodgkinson et al., 2016); hence, in situ modulation of host
cellular responses is unlikely to be mediated by a single or
by few factors, but rather by a more complex and synergistic
combination of several paracrine agents, such as those conveyed
by MSC-secreted EV. Indeed, stem cell-EV cargo can include a
mixture of bio-active lipids, proteins and genetic information and
has been increasingly scrutinized as therapeutic agent to enhance
tissue repair (Lai et al., 2011; Chen et al., 2017).
Shedding New Light on Stem Cell-EV
The shift in perspective from the stem cell genome to
their secretome, with specific focus on the secreted EV, is
transforming the idea of therapeutic application of stem cells in
regenerative medicine. Indeed, by replacing cell transplantation
with administration of secreted EV, many concerns and limits
related to safety and feasibility could be mitigated. Exploiting
stem cell-mediated effects via cell-free delivery of paracrine
factors may result in a more feasible and clinically translational
therapy. Mounting evidences support the working hypothesis
of stem cell-EV as promising tool for therapeutic enhancement
of cardiac repair mechanisms; several independent studies
have reported that intra-myocardial injection of adult MSC-
EV in rodent acute MI and I/R models markedly enhanced
neovascularization, preserved cardiac function, reduced infarct
size and counteracted pathological remodeling (Bian et al., 2014;
Teng et al., 2015; Liu et al., 2017; Barile et al., 2018). Importantly
some evidence suggests this may occur in a dose dependent
fashion, as shown by Arslan et al. (2013). When injecting either
1, 4, or 16 µg/kg of exosomes intravenously in a mouse model
of I/R, only the latter two were shown to have cardioprotective
potential; this was further confirmed by using a 0.4 µg/ml MSC-
Ex buffer in an ex vivo I/R injury setting (Arslan et al., 2013).
Therefore, in recent years growing interest has been addressed
to the comprehensive characterization of the cardio-active
paracrine profile of stem cell-secreted EV, in order to define
an advanced therapeutic medicinal product (ATMP) for future
cardiac regenerative medicine (Perrino et al., 2017; Sluijter et al.,
2018). Consequently, much attention has been focused on the
mechanisms of action dictated by their functional cargo. Despite
being very small entities, stem cell-EV (and Ex in particular)
represent relatively complex biological conveyors of inter-cellular
communication via soluble factors as well as direct horizontal
transfer of RNA molecules, mostly represented by miRNAs, as
extensively reviewed in Hill et al. (2013); Lai et al. (2016), Bjørge
et al. (2017), and Kim et al. (2017).
Indeed, an increasing number of investigations have been
suggesting that stem cell-EV can mediate cardiac repair by
delivering miRNA content to recipient cells within the heart,
thus remarkably reprogramming target cell genetic information.
Sahoo et al. (2011) were the first to report that human circulating
CD34+ hematopoietic precursors release EV endowed with pro-
angiogenic miR-130a and miR-126-3p. These EV had relevant
potential in inducing neovascularization within the ischemic
mouse tissue, as acting on VEGF-, ANG1-, ANG2-, and MMP9-
signaling pathways (Sahoo et al., 2011; Mocharla et al., 2013;
Mathiyalagan et al., 2017). Similarly, EV from human UC
MSC have shown to contained various miRNAs crucial for
cardiac and angiogenic cell differentiation of target cells, such
as miR-199a-3p, miR-199a-5p, miR-23a-3p, miR-24a, miR-132-
3p, miR-21-5p (Bobis-Wozowicz et al., 2016). Murine MSC
have also been described to influence cardiac repair following
MI in mice by miR-22 transfer via EV delivery, resulting
in cardiomyocyte survival and inhibition of the profibrotic
marker MeCP2 expression (Feng et al., 2014). Furthermore, the
direct effect of EV/Ex cargo on cardio-protection was shown
in a recent study by Luther et al. (2018) where an important
contribution of miR21a-5p, present in MSC-Ex, was recognized
both in vitro and in vivo. Importantly, by using Ex isolated
from miR21a-knockout cells or by using miRNA mimics, they
were able to conclude that the delivery of miRNA21a-5p into
cardiomyocytes via exosomes and the downregulation of its
target is at least partly responsible for apoptosis reduction
in vitro and in vivo, with a smaller infarct size after I/R injury
(Luther et al., 2018). Besides MSC, mouse embryonic stem cell
(ESC)-EV, including Ex, significantly contributed to improve
neovascularization, cardiomyocyte survival, and to limit fibrosis
post infarction possibly acting via the miR-290-295 cluster (Khan
et al., 2015). Despite the lack of a general consensus on the
most cardio-active miRNA molecular signature within stem cell-
EV/Ex, cumulative evidences, reinforced by comprehensive RNA
sequencing, indicate the superior therapeutic effect of EV/Ex over
MSC alone is due to their specific miRNA enrichment (Shao et al.,
2017). Likewise, a recent study from our group indicated that
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human amniotic fluid stem cell-EV (hAFS-EV) are specifically
enriched with miRNAs over proteins or other soluble factors;
notably direct trafficking of miR-210 and miR-199a-3p from
hAFS-EV to responder cells were suggested to drive pro-survival
and proliferative effects in recipient human dermal fibroblast
and murine myoblasts, which showed significant increase of such
putative molecular candidates (Balbi et al., 2017). This may lay
the foundations for further studies to pinpoint specific signaling
pathway/molecular targets with relevant therapeutic application
for cardiac repair and regeneration; indeed, these miRNAs have
been described to exert remarkable effects on the myocardium
in vivo, as potent drivers of local angiogenesis and cardiomyocyte
renewal (Eulalio et al., 2012; Arif et al., 2017). As well, to
instruct the cardiac tissue to enhance repair and counteract
detrimental remodeling following injury, it is crucial to act within
the very acute response phase; considering their prompt effect,
timely modulation of specific signaling pathways by EV-mediated
paracrine action may offer an interesting working strategy.
Nevertheless, additional functional mechanisms have been
reported to elucidate stem cell-EV therapeutic effects. For
example, Notch-pathway has been proposed as molecular
candidate of paracrine intercellular communication, since Jagged
1-endowed MSC-EV induced robust and specific angiogenic
response both in vitro and ex vivo by Matrigel plug assay
(Gonzalez-King et al., 2017). As well, human ESC-derived
MSC were shown to release Ex restoring the myocardium
ATP production while decreasing oxidative stress via functional
replenishment of glycolytic enzymes from their cargo into the
injured myocardium in a preclinical mouse model of I/R injury
(Arslan et al., 2013; Lai et al., 2013).
Critical Aspects for Future Cardiac
Paracrine Therapy
In the last few years a variety of stem cells have been scrutinized
for cardiac repair, including peripheral blood-derived progenitor
cells, BM- and adipose-derived MSC, fetal and perinatal stem and
progenitor cells, embryonic and iPSC (as extensively reviewed in
Abdelwahid et al., 2016). Given the promising cardioprotective
and pro-angiogenic potential of stem cell-EV/Ex, many efforts
have recently been focused on identifying the ideal cell source for
scaling up the production of EV and Ex as advanced medicinal
product for ischemic-related diseases.
Cardiovascular disease patients need prompt therapeutic
intervention and it would be ideal to have access to regenerative
“off-the-shelf ” products for simple administration; hence, stem
cells might be used as a “drug store” to produce a highly efficient
EV/Ex formulation to provide enhancement of cardiac repair
(Figure 1). In this scenario, isolation feasibility and elevated
self-renewal represents key aspects of the optimal stem cell
source to be exploited for future paracrine therapy. Human adult
progenitor cells, including MSC, can be isolated from a variety of
post-natal tissues and obtained from discarded samples as clinical
waste or leftover material during ordinary surgical or screening
procedures (blood sampling, liposuction, BM transplantation,
etc.). However, they can be affected by low yield and limited self-
renewal potential, as they are often influenced by donor age (van
Vliet et al., 2010). On the contrary, iPSC may overcome classical
drawbacks of adult MSC by offering, in principle, unlimited
production of stem and progenitor cells in vitro. Indeed, when
comparing cardiac reparative effects of murine iPSC against their
secreted EV, the latter showed superior paracrine potential in
a preclinical model of I/R injury in mouse, thus representing
an appealing therapeutic option by offering the benefits of iPSC
therapy, but without the risk of tumorigenicity (Adamiak et al.,
2017). Yet, iPSC technology can be challenging, costly and time
consuming. The more recent characterization of fetal (with non-
embryonic origin) and perinatal progenitor cells, have broadened
the options. Fetal stem cells isolated either from AF (De Coppi
et al., 2007) or villi (Poloni et al., 2008) as easily collected
from leftover sample obtained during routine prenatal screening;
perinatal stem cells can be isolated at birth from discarded extra-
embryonic annexes, such as UC, including the WJ (Wang et al.,
2004; Tauro et al., 2012), and placenta membranes (Magatti et al.,
2016), thus representing an easily accessible source progenitors
available in large amount and free from any ethical concern.
Fetal and perinatal stem cells can offer specific advantages
over adult MSC, since they are endowed with outstanding self-
renewal and possibly higher paracrine potential than the adult
ones, being developmentally more immature. Indeed, human
UC-MSC-EV systemically injected into a preclinical rat model
of MI sustained cardiac systolic function after 4 weeks, while
offsetting fibrosis and cells apoptosis (Zhao et al., 2015). Specific
interest has also been recently dedicated to the paracrine potential
of human amniotic fluid-derived stem cell-EV, as described
by few independent studies mediating therapeutic pro-survival,
angiogenic, and anti-inflammatory effects (Balbi et al., 2017;
Mellows et al., 2017; Sedrakyan et al., 2017; Beretti et al., 2018).
Stromal cell function and secretory potential can be critically
determined by the microenvironment scenario. Notably, fine
tuning of the microenvironment in vitro can significantly and
quantitatively influence the cell secretome (Leuning et al., 2018).
Therefore, in vitro cell-preconditioning can be adjusted in order
to select the ideal cell culture conditions to prime stem cell-
EV with optimal cardioprotective and pro-angiogenic potential
for therapeutic relevance. For instance, short term hypoxic
stimulation has been increasingly used to enrich MSC-EV and
Ex with trophic paracrine factors. Delivery of these vesicles
resulted in promotion of neovascularization and cardiac repair
in preclinical rodent models of MI. The putative mechanisms
of action have been reported to involve increased expression
of nSMase2, which is critical for exosome biogenesis and EV-
mediated transfer of miR-210 (Bian et al., 2014; Gonzalez-
King et al., 2017; Zhu et al., 2017). Likewise, transgenic
overexpression of specific cardio-active factors within stem cells
has been employed to enhance the healing capacity of their
secreted EV; overexpression of HIF-1α in human dental pulp-
MSC led to secretion of enhanced Jagged 1-loaded exosomes
that triggered the angiogenic differentiation of endothelial cells
(Gonzalez-King et al., 2017). Moreover, Li et al. (2010) previously
showed that rat (bone marrow) BM-MSC genetically modified
to significantly increase GATA-4 expression, are endowed with
noteworthy paracrine pro-survival and angiogenic potential
in the ischemic environment. They then exploited the same
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FIGURE 1 | Schematic representation of the most relevant effects of extracellular vesicle-mediated intercellular communication within the injured myocardium as
providing: (A) cardio-protection and cardiac repair by exogenous stem cell-EV/Ex; (B) paracrine modulation of the cardiac microenvironment by EV/Ex derived from
CPC either activated in situ (i) or previously isolated and expanded in vitro (ii); and (C) fine tuning of adult resident cardiomyocyte and cardiac stromal cell behavior by
their mutual EV/Ex modulatory exchange during adaptive response to stress. ATMP, advanced therapy medicinal product.
working strategy to boost the cardioprotective paracrine effect of
MSC-Ex in a preclinical rodent model of I/R injury; exosomal
reprogramming of resident cardiomyocytes via the delivery of
miR-19a targeting PTEN and BIM protein expression resulted
in sustained activation of Akt and ERK signaling pathway, with
significant recovery of cardiac function and decreased infarct size
(Yu et al., 2015).
Stem cell-EV are being increasingly considered as biological
enhancers of heart repair mechanisms (Madonna et al., 2016), yet
little is known about their cardiac regenerative potential to trigger
functional activation of endogenous CPC and responsive resident
cardiomyocyte proliferation. Currently only a few studies have
provided evidences of such critical effects. Mouse ESC-Ex
have been demonstrated to prompt rodent resident c-KIT+
CPC survival, proliferation, and cardiac commitment several
weeks after in vivo administration, with restitution of de novo
cardiomyocytes in the ischemic heart, possibly via specific miR-
294 transfer (Khan et al., 2015). Similarly, human iPSC-secreted
shedding MV exerted in vitro proliferative and protective effects
on human cardiac MSC possibly via direct transfer of miR-
92b and elicited their cardiac and endothelial differentiation
potential (Bobis-Wozowicz et al., 2015). Moreover, rat BM-MSC-
Ex showed to prime c-KIT+ rat neonatal CPC by reprogramming
their miRNA landscape, thus targeting a broad range of
biological functions, from positive regulation of cell cycle, up
to cell differentiation and response to hypoxia; such MSC-Ex
preconditioning strategy also boosted CPC angiogenic ability and
increased their in vivo functional potency after transplantation
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into the rat ischemic myocardium (Zhang et al., 2016). While
such data is surely encouraging and very promising, further
comprehensive studies are required to specifically assess stem
cell-EV potential to sustain functional restoration of myocardial
renewal via cardiomyocyte proliferation as well.
While standard cell therapy has been almost completely
dismissed, high expectations have now been put into the
therapeutic efficacy of stem cell-EV as paracrine facilitators of
cardiac repair and regeneration. Indeed, they may represent
an appealing alternative cell-free curative modality that could
be clinically and translationally effective, safer, and cheaper.
However, such a novel approach is still in its infancy as it requires
extensive testing to validate EV safety and functional efficacy in
the long term.
A CLOSER LOOK: ENDOGENOUS
CARDIAC PROGENITOR CELL-EV FOR
REPAIR AND REGENERATION
Mending Broken Hearts From Within:
The Biological Relevance of Cardiac
Progenitor Cells
Cardiac progenitor cell represent a heterogenous population
of cells scattered throughout the cardiac tissue, including atria,
ventricles, and the epicardium (Bollini et al., 2011). They
have been described expressing early cardiac development
markers, thereby suggesting promising cardiovascular and
cardiomyogenic potential which makes them particularly
interesting as a therapeutic target for cardiac regeneration.
The first functional characterization of CPC came from a
study by Beltrami et al. (2003), describing a population of
resident progenitor cells found throughout the ventricular and
atrial myocardium expressing markers that were up to that
point associated with hematopoietic progenitor cells, including
Stem cell antigen-1 (Sca-1) and the tyrosine kinase receptor
c-KIT. Upon isolation, c-KIT+, Lin-, CD45- CPC were shown
to differentiate into cardiac cell types and to contribute to repair
of the injured myocardium when transplanted into a preclinical
rat model of MI (Linke et al., 2005) by significantly decreasing
scarring and fibrosis, and possibly by differentiating into cardiac
cells. In the following years several other studies followed and
focussed on putative different sub-populations of mammalian
CPC (Gaetani et al., 2014). These were mainly based on the
expression of well-recognized stem cells markers (i.e., c-KIT or
Sca-1), by specific isolation and in vitro culture protocols, or
by their developmental origin, as extensively reviewed in Bollini
et al. (2011).
Within the human CPC scenario, two individual progenitor
populations have been broadly investigated are the human
c-KIT+ CPC and the so-called CS or CDC. Since these cells can
be easily obtained from cardiac specimens obtained as clinical
waste during routine cardiac surgery, their clinical translation
was readily pursued. The promising results of c-KIT+ CPC
transplantation in improving post-infarction left ventricular
(LV) dysfunction in preclinical animal models, resulted in the
SCIPIO-Cardiac Stem Cell Infusion in Patients With Ischemic
CardiOmyopathy phase 1 clinical trial1. Despite initial reports
suggesting that intracoronary infusion of autologous c-KIT+
CPC improved LV systolic function and reduced infarct size
in patients with HF after MI (Bolli et al., 2011; Chugh et al.,
2012) recently concern has been expressed over the integrity
of previously published data (The Lancet Editors, 2014). CS,
a heterogeneous population of cells able to spontaneously
generate three-dimensional structures, have been described by
Messina et al. (2004) to have stem-like, cardiovascular and
cardiomyogenic properties (Smith et al., 2007) as well as
regenerative influence on the damaged cardiac tissue (Johnston
et al., 2009). Likewise, their promising profile led in 2009 to
the CADUCEUS-CArdiosphere-Derived aUtologous Stem CElls
to Reverse ventricUlar dySfunction clinical trial to test dose
escalation safety and efficacy of intracoronary delivery in patients
with ischemic LV dysfunction and MI. While no difference in
LV ejection fraction was reported at 6 months follow-up, CPC-
treated patients showed reduction in scar mass and improved
regional contractility (Makkar et al., 2012).
Another human derived population that has been described,
but has not yet been pursued for clinical application, is
represented by Sca-1+ CPC. These cells have been shown
to differentiate into beating cardiomyocytes and endothelial
structures in vitro when stimulated with TGFβ or VEGF,
respectively (Goumans et al., 2008). The transplantation of
undifferentiated Sca-1+ CPC into the MI mouse heart resulted
in enhanced cardiac function and expression of human
cardiomyocyte markers at 12 weeks follow-up (Smits et al., 2009).
However, in short-term follow-up, the positive effect on cardiac
function was observed in absence of differentiation (Den Haan
et al., 2012), suggesting a paracrine effect of the transplanted
cells.
More recently, a population of CPC residing within the
epicardium – the outer layer of the heart – has gained
growing attention as a promising target for enhancing
cardiac repair and regeneration (Moerkamp et al., 2016;
Smits et al., 2018). During embryonic development there is a
clear contribution of epicardial-derived cells (EPDC) to cardio-
genesis. EPDC contribute to the smooth muscle component
of the coronary vasculature, to interstitial fibroblasts and
potentially to ventricular cardiomyocytes, although the latter
is still under debate. Moreover, embryonic EPDC contribute
soluble factors that stimulate the growth of the myocardium.
In the adult heart, the epicardium is a quiescent layer, only
to become activated after MI, as shown by an upregulation
of embryonic markers, proliferation and migration (Zhou
and Pu, 2011). Given the developmental ability of EPDC, and
their partial activation post-injury, the epicardium and its
derivatives are an intriguing endogenous cell type to pursue
with respect to cardiac repair. Interestingly, Smart et al. (2011)
showed that priming the epicardial response by systemic
injection of the small cardio-active peptide thymosin β4 prior
to infarction resulted in an increased activation and enhanced
cardiac function, potentially accompanied by differentiation
1https://clinicaltrials.gov/ct2/show/NCT00474461
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of EPDC into cardiomyocytes. EPDC can be isolated and
cultured from different human cardiac samples including
adult atrium samples and fetal cardiac specimens (van Tuyn
et al., 2007; Moerkamp et al., 2016). When injected into to
the infarcted mouse heart, EPDC where shown to positively
affect cardiac function and stimulate local angiogenesis up to
6 weeks post-MI (Winter et al., 2007), but in the absence of
the transplanted cells’ survival, thereby arguing for a paracrine
contribution of EPDC to cardiac repair. This was further
confirmed by studies where the conditioned medium of cultured
mouse EPDC was shown to stimulate angiogenesis, and its
injection into the heart resulted in reduced infarct size and
enhanced cardiac function and local angiogenesis (Zhou et al.,
2011).
CPC Paracrine Potential via EV-Based
Communication
Recent studies have emphasized that ex vivo cultured CPC show
low engraftment and very limited differentiation potential within
the injured myocardium (Winter et al., 2007; Smits et al., 2009;
Feyen et al., 2017), while positive effects on cardiac function could
have been recorded (Zwetsloot et al., 2016). Indeed, a very recent
study based on an optimized genetic lineage trace has questioned
the cardiomyogenic differentiation potential of the endogenous
so-called cardiac “stem” cells or CSC, as showing that, opposite to
what happens during embryonic cardiogenesis, in the adult heart
de novo cardiomyocytes do not derive by putative resident cardiac
stem cells (Li et al., 2018).
Thus, given that the biological profile of CPC is still
quite controversial in terms of specific cardiovascular and
cardiomyocyte commitment, there is now a general consensus
on their substantial paracrine activity to exert cardioprotective
effects, while increasing cardiac function. Hence, attention
has moved to the paracrine profile of these cells with a
particular interest in the functional characterization of CPC-EV,
including Ex.
Indeed, several studies have highlighted the remarkable role of
CPC-EV in enhancing cardiac repair mechanisms and promptly
modulating acute inflammation, while sustaining long-term
cardiac function. Ibrahim et al. (2014) recently showed that
the EV secreted by CDC recapitulated the regenerative effects
of the whole CDC secretome, including their pro-survival,
proliferative and angiogenic effects on cardiac cells, both in vitro
and in vivo. Similar beneficial results were also validated by
an independent study from Barile et al. (2014) in which the
cardioprotective effect of EV obtained from CPC derived from
atrial appendage explants was tested against those derived from
human dermal fibroblast. Indeed, human CPC-EV were shown
to be the most cardio-active component of the progenitor cell
paracrine secretome, as rodent infarcted hearts injected with
EV from CPC, but not from control fibroblasts, prevented
cardiomyocyte from apoptosis, enhanced neovascularization,
and improved LV ejection fraction (Barile et al., 2014). Moreover,
Tseliou et al. (2015) confirmed the therapeutic potential of
cardiosphere-derived-EV in reprogramming fibroblast behavior
and secretome, by making them less pro-fibrotic, more
angiogenic and cardioprotective. Lately, human CDC-EV
therapeutic feasibility has also been validated in a large animal
preclinical model of MI in pigs, by intracoronary (IC) or
open-chest intramyocardial (IM) delivery, after reperfusion in
acute or chronic settings (Gallet et al., 2017; Nguyen et al., 2018).
Local Ex delivery proved to be effective in decreasing fibrosis
and adverse remodeling, while improving cardiac function after
a single dose or follow up treatments in the long term; notably,
the more clinically suitable IC administration did not produce
equivalent beneficial results, suggesting that delivery route and
timing are critical aspects for future cardiac paracrine therapy
(Gallet et al., 2017).
CDC-Ex have been shown to horizontally transfer into
target cells, resulting in critical decrease of scar mass and
significant improvement of global cardiac function following
MI. Notably, miR-146a was identified as particularly enriched
within CDC-Ex and playing an important role in mediating
some of the nanovesicle trophic effects, such as inhibiting
pathological remodeling and increasing viable myocardium mass
in a murine preclinical model of MI (Ibrahim et al., 2014).
Yet, selective administration of miR-146a mimic reproduced
only some -not all- the benefits obtained via CDC-Ex,
suggesting that, while playing a significant role as part of their
cargo, it cannot be considered as the individual molecular
candidate to confer comprehensive therapeutic benefit to the
injured heart. These results suggest a more cautious attitude
toward the translation of EV/Ex biology into the clinical
scenario and functional identification of discrete factors within
their cargo as future pharmacological molecules with cardio-
regenerative effects cannot be considered a straightforward
approach yet.
Human CPC-EV have been also described as carrying cardio-
active miRNAs including miR-210, miR-132, and miR-146a-
3p, which affect the expression of Ephrin A3 and PTP1b
in the responder cells, and subsequently lead to inhibition
of cardiomyocyte apoptosis and enhancement of angiogenic
differentiation by endothelial cells (Barile et al., 2014). Another
relevant therapeutic miRNA enriched in CDC-EV is miRNA-
181b (De Couto et al., 2017) as described to convey remarkable
immunomodulatory effects, by decreasing CD68+ macrophages
infiltrating in the heart after MI. Yet, miRNAs are not the
only “usual suspects” driving EV- and Ex-derived regenerative
effects. Recently, another class of non-coding RNA, the
Y RNAs, has been reported to be plentiful in CPC-EV.
Cambier et al. (2017) showed that a Y RNA fragment highly
enriched in human CDC-EV can be actively transferred into
macrophages, endowing them with cardioprotective potential
and mediating strong anti-inflammatory and pro-survival effects
in rodent hearts undergoing I/R injury (Cambier et al.,
2017).
CPC-EV can directly deliver proteins to recipient cells as
well. For instance, the pro-angiogenic effects of human Sca-1+
CPC-EV on endothelial cells in vitro and in vivo was shown
to be regulated through high levels of EMMPRIN within
these vesicles (Vrijsen et al., 2016). Notably, when exosome
EMMPRIN was blocked via neutralizing antibodies, authors
detected a significant reduction in EV-mediated angiogenic
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effects in vitro. Such result was further enhanced by shRNA-
induced knock-down as EMMPRIN-deprived EV failed to
stimulate network formation in a Matrigel tubule assay to the
same extend as control untreated EV. Since enhancement of
local angiogenesis is critical to optimize cardiac repair and
improve functional recovery in the long term, this study provides
interesting insights about exploiting specific EV molecular
strength to drive effective pro-angiogenic responses within the
damaged heart, such as vessel growth into the border zone
and infarcted area. Similarly, a recent study compared the
paracrine potential of human CPC-EV against the ones derived
from bone marrow-derived mesenchymal stromal cell (BM-
MSC), in an rodent model of MI (Barile et al., 2018). Results
revealed that the superior cardioprotective role of CPC-EV
could be related to a specific mechanism of action in the
vesicle release of IGF-1 as mediated by PAPP-A, which was
significantly enriched in the EV secreted by CPC over BM-MSC
ones (Barile et al., 2018). The functional role of PAPP-A as
master regulator of CPC-EV potential was further validated by
transfecting cells with PAPP-A-specific siRNA; EV from PAPP-
A-knockdown CPC did not inhibit cardiomyocyte apoptosis
in vitro, nor counteracted LV dysfunction after permanent
coronary ligation in vivo in rodents, hence highlighting the
pivotal operative role of such protein on CPC-EV surface. Of
interest, this study suggested a mechanism of action driving
vesicle cardioprotective capacity other than the traditional
view on EV mainly acting via intracellular delivery of their
molecular cargo to target cells, hence providing new starting
points for future strategies influencing cardiac repair and
remodeling.
Several studies have addressed and comprehensively analyzed
the paracrine potential of endogenous CPC-EV/Ex in optimizing
cardiac repair by exerting beneficial cardio-protective,
immunomodulatory, and angiogenic effects. Nevertheless,
in order to define whether CPC-EV might represent an ideal
future therapeutic candidate over exogenous stem cell-EV,
further investigation should be provided on their cardio-active
potential to restore and efficiently sustain myocardial renewal
following injury. Indeed, so far very few studies have addressed
such aspect, which is one of the most challenging for cardiac
regenerative medicine. To the best of our knowledge, currently
available data on CPC-EV potential to trigger cardiomyocyte
proliferation is limited to in vitro analyses (Barile et al., 2014;
Ibrahim et al., 2014).
Moreover, since CPC offer the unique advantage to mediate
endogenous cardiac regeneration from within the cardiac tissue, a
consensus on the most effective strategy to unlock their paracrine
potential in situ is strongly needed. Indeed, adult CPC are
usually quiescent or dormant and not efficiently responsive when
facing injury or disease. Ideally, since they represent endogenous
progenitors residing within the myocardial tissue, it would be
advantageous to trigger their paracrine potential via EV release
in situ by appropriate stimulation. Otherwise, CPC can be easily
isolated from clinical waste specimen during routine cardiac
surgery, ex vivo expanded and preconditioned with specific
stimuli as for exogenous stem cells (Figure 1); however, being
less immature and tissue-specific committed progenitors, such
high level of processing can influence their behavior, secretome
composition and yield.
RESIDENT CARDIOVASCULAR CELL
INTER-COMMUNICATION: THE
CARDIOMYOCYTE-FIBROBLAST EV
AXIS
A whole body of experimental research indicates that
cardiomyocytes and cardiac stromal cells, especially fibroblasts
(Fib), influence one another via cell-to-cell contact and, to a
larger extent, paracrine mediators (Howard and Baudino, 2014;
Figure 1).
Several authors showed that co-culturing cardiac stromal
cells and cardiomyocytes or incubating either cell population
with the culture medium conditioned by the other one, results
in significant structural and functional modifications. In most
cases, it was demonstrated that cardiac Fib affect aspects of
cardiomyocyte biology, such as hypertrophy (Cartledge et al.,
2015), electrical activity (Pedrotty et al., 2009), contractility
(LaFramboise et al., 2006), and viability (Shivakumar et al., 2008).
Nonetheless, it was also found that other stromal cell types,
such as endothelial cells, modulate cardiomyocytes in culture
systems (Wang et al., 2014) as well as that cardiomyocytes may
in turn regulate Fib and other non-cardiomyocyte populations
(Cartledge et al., 2015; Garcia et al., 2016).
A second line of evidence consists of experiments with animal
models, in which elimination of single cardiac Fib-secreted
factors by genetic manipulation led to pathological ventricular
remodeling in response to pressure overload (Pellieux et al., 2001;
Sanada et al., 2007; Takeda et al., 2010). Overall, these studies
have confirmed that the interaction between cardiomyocytes and
non-cardiomyocytes described in vitro does occur also in vivo,
and that any perturbation of this crosstalk invariably causes
myocardial disease and HF. Interestingly, the same mediators
may transmit signals from cardiomyocytes to stromal cells and
vice versa. For instance, transgenic mice overexpressing the
Notch ligand, Jagged1, on the surface of cardiomyocytes (which
activates Notch signaling in contiguous cardiomyocytes and non-
cardiomyocytes) display enhanced proliferation of CPC and
cardiomyocytes in neonatal life, and reduced cardiomyocyte
hypertrophy, blunted cardiac Fib expansion and fibrosis, and
increased numbers of Sca-1- and Nkx2.5-positive CPC following
pressure overload when adult (Nemir et al., 2014). On the other
hand, genetic or pharmacological inhibition of Notch signaling in
cardiac endothelial cells impairs the supply of fatty acids across
the endothelium to cardiomyocytes, which thereby switch to
maladaptive glucose-dependent energy metabolism; along with
uncontrolled angiogenesis, this derangement promotes HF (Jabs
et al., 2018).
Within this scenario of complex intercellular
communications, a role for EV has been repeatedly proposed.
In a seminal work, Thum et al. (2008) demonstrated that
miR-21 stimulates cardiac Fib survival and activity, up to
the point that silencing of miR-21 by a specific antagomir-21
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significantly reduced LV fibrosis and dysfunction in mice
subjected to pressure overload by transverse aortic constriction.
Building on these findings, these and other authors subsequently
showed that cardiac Fib secrete Ex enriched for miRNAs and
miRNA passenger strands, despite these latter being predicted
to be degraded during miRNA biogenesis (Bang et al., 2014). In
particular, miR-21 passenger strand (miR-21∗) is highly expressed
in Ex from cardiac Fib, is further increased by angiotensin II,
and is implicated in hypertrophy of cardiomyocytes (Bang
et al., 2014). Consistent with these observations, repression of
miR21 by means of antagomir-21 and pharmacological blockade
of miR-21∗ counteracted transverse aortic constriction- and
angiotensin II-initiated LV hypertrophy, respectively (Thum
et al., 2008; Bang et al., 2014). Other investigators subsequently
confirmed that Ex are synthetized by cardiac Fib upon exposure
to angiotensin II and cause cardiomyocyte hypertrophy in a
paracrine manner, and that found that inhibition of Ex release
attenuated angiotensin II-elicited cardiac hypertrophy (Lyu et al.,
2015). Remarkably, cardiac Fib Ex were also shown to induce a
cell-intrinsic renin-angiotensin system in cardiomyocytes (Lyu
et al., 2015), and angiotensin II-primed cardiomyocytes were
reported to induce miR21 signaling in cardiac Fib (Lorenzen
et al., 2015), substantiating the concept that the crosstalk between
cardiomyocytes and stromal cells is bidirectional and at multiple
levels.
To add a further layer of complexity to the EV-mediated
cell inter-communication within the myocardium, there is
evidence that EV with potential paracrine effects are also
released by cardiomyocytes, in spite of being these cells usually
considered non-secretory. A pioneering study conducted in 2007
demonstrated the ability of cultured adult cardiomyocytes to
secrete Ex containing HSP60, which is involved in regulation
of cardiomyocytes apoptosis and inflammation and, therefore,
may play a primary role in myocardial pathology (Tian
et al., 2013). Expanding on these findings, it was subsequently
observed that Ex secretion by cardiomyocytes is tightly regulated
by the microenvironment and by ROS production and that
cardiomyocytes-derived Ex have a peculiar protein content
pattern, enriched for sarcomere and mitochondrial proteins,
which is related to the stimuli driving EV formation (Malik
et al., 2013). In fact, the effects of Ex from cardiomyocytes
was different depending on the oxygen concentration to which
cardiomyocytes were exposed: Ex released by cardiomyocytes
in hypoxic condition displayed an increased cardioprotective
activity compared to normoxic condition, with enhanced
angiogenesis. This latter was at least in part due to higher
levels of miR-222 and miR-143 (Ribeiro-Rodrigues et al., 2017).
Other molecules highly present in cardiomyocyte EV are mRNAs,
with 423 out of the 1520 mRNAs detected being connected in
biological networks, in particular regarding energy metabolism
(Waldenström et al., 2012).
A major limitation in investigating EV and Ex from
cardiomyocytes is that it is not possible to set a human culture,
and studies typically rely on various cell types – the murine
cardiomyocyte HL-1 cell line, the rat cardiomyoblast H9c2
cell line, rat primary fetal cardiomyocytes and even adult rat
cardiomyocytes (Gupta and Knowlton, 2007; Waldenström et al.,
2012; Ribeiro-Rodrigues et al., 2017), none of which reliably
reproduces the main features of human adult cardiomyocytes.
To overcome this drawback, the use of cardiomyocytes obtained
from iPSC may hold great promises (Denning et al., 2016).
OPEN QUESTIONS
Cell-secreted vesicle biology is becoming a rapidly expanding
field with dramatic impact on future cardiac regenerative
medicine, given the noteworthy role of EV and Ex in driving
heart repair and regeneration, while also regulating interaction
among resident cardiomyocytes and surrounding stromal cells,
as summarized in schematic Figure 1. Nonetheless, many critical
aspects need further investigation in order to clearly define their
clinical translational potential.
Extracellular vesicles represent a very heterogeneous
population, being enriched with both Ex and MV. While several
independent studies suggest Ex over MV as key mediators of
biological modulatory effects (Barile and Vassalli, 2017; Mol
et al., 2017), a general consensus on the most functionally
cardio-active fraction between the two hasn’t been reached yet,
since the comprehensive paracrine profile of Ex over MV is
still undefined (Van Niel et al., 2018). Indeed, the structural
heterogeneity of EV represents a challenge for our understanding
of their biological functional role, as currently much remains
unspecified regarding the detailed origin, regulatory pathways of
secretion and cell targeting mechanisms. Likewise, tumorigenic
Ex themselves have been lately described to be further fractioned
into distinct subsets: large exosomes (ranging from 90 up to
120 nm), small exosomes (from 60 to 80 nm) and a third
class of non-membranous nanoparticles defined as exomeres
(about 35 nm). This additional sub-classification seems to be
recapitulated by distinct proteomic, lipid, and nucleic acid
content that influences organ biodistribution and pleiotropic
effects related to cell metabolism, proliferation and secretion
pathways (Zhang et al., 2018).
When considering clinical translation feasibility for future
therapy, the overall reproducibility of the isolation methods as
well as the efficiency of the product must be carefully considered.
For example, it has yet to be determined whether endogenous
CPC might be a preferential source over exogenous stem cells to
harness cardio-active EV/Ex from. While CPC have to be either
powerfully reactivated in situ with specific stimuli or harvested
by invasive procedure and then expanded in vitro to exploit their
paracrine potential, exogenous MSC can be obtained by a variety
of clinical waste samples that may be much easily available.
Likewise, iPSC may offer the advantage of being cultured in
large quantities from a single isolation, providing a reliable
background. Yet, given their ability to produce cardiac cell types,
the CPC populations represent an interesting cell source to
focus on, and may be especially efficient when cultured under
conditions that resemble the injured myocardium (e.g., hypoxia
or extracellular matrix composition).
Another relevant aspect influencing EV biology is related
to their isolation protocol, from either cell-conditioned culture
medium or biological fluids, including blood serum. Many
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different techniques have been reported and characterized:
differential ultracentrifugation, immunoaffinity capture,
ultrafiltration, size-exclusion chromatography, polymer-based
precipitation up to state-of-the-art microfluidics (Théry et al.,
2006; Chen et al., 2010; Merchant et al., 2010; Tauro et al.,
2012; Jørgensen et al., 2013; Heinemann et al., 2014). Therefore,
the ideal method for EV clinical translation and their scale-
up standardization as future ATMP still represents a major
challenge. Indeed, while most protocols aim at increase efficiency
and efficacy of the isolation yield, many of them present relevant
concerns about contamination of cell-derived molecules or do
not offer reliable EV sub-fractioning into Ex versus MV from
cell-conditioned medium as well as biological fluids (Baranyai
et al., 2015; Sluijter et al., 2018). Recently, asymmetric flow field-
flow fractioning has opened up a new promising scenario for
the efficient isolation of distinct EV subpopulations, via highly
reproducible, fast, simple, label-free technology (Zhang et al.,
2018).
These methodological issues also represent a current major
limitation to the possibility of measuring EV in the bloodstream
for diagnosis of cardiac disease. In principle, increased circulating
concentrations of EV containing myocardial-specific markers
(proteins, lipids, and RNA) may allow the recognition of
some cardiac disorders earlier and/or more accurately than
by using conventional biomarkers, such as troponins and
natriuretic peptides (Sluijter et al., 2018). In fact, seminal
work has pinpointed EV content profiles selectively associated
with acute coronary syndromes (de Hoog et al., 2013), HF
(Wong et al., 2015), and chemotherapy-induced cardiomyopathy
(Yarana et al., 2018). Nonetheless, the aforementioned technical
aspects should not be overlooked and future prospective studies,
designed ad hoc, are warranted to confirm the value of EV as
biomarkers of cardiovascular disease in the clinical arena.
Extracellular vesicles participate in myocardial cell inter-
communication and, in principle, novel therapies for LV
hypertrophy and HF may target the cardiomyocyte-cardiac
stromal cell paracrine axis or specific mediators that their EV
may carry. Moreover, being EV also involved in physiological
responses to stress, it will be extremely challenging to tailor
innovative therapeutic approaches that inhibit detrimental
effects, while preserving EV beneficial function in maintenance
of cardiac homeostasis.
As several studies have emphasized the direct effect on EV
cargo on their target cells to influence for instance angiogenesis
(Vrijsen et al., 2016) or cardio-protection (Luther et al., 2018),
establishing whether the combination of discrete paracrine
factors (either distinct soluble factors or nucleic acid information)
identified within the vesicle cargo can completely recapitulate
EV cardioprotective and/or regenerative effects can offer critical
information for future pharmacological applications. As well,
the most efficient and less invasive administration protocol
for putative EV-based cardiac paracrine therapy has to be
characterized yet; indeed, while single administration during
angioplasty procedure may be clinically feasible, maintenance
of therapeutic levels in the long term might require follow-
up treatments which should be delivered to the myocardial
tissue as exclusively as possible. Moreover, dose-response effects
need to be comprehensively investigated; currently information
on this specific aspect is quite limited and general consensus
on the most appropriate method to measure the EV dose
to be employed has not been reached yet. Indeed, in most
studies the dose of EV administered in vitro and/or in vivo
has been indicated by number of EV particles/µl (Ibrahim
et al., 2014; Gallet et al., 2017; Barile et al., 2018) or by
µg of EV total protein (Arslan et al., 2013; Barile et al.,
2014; Balbi et al., 2017), or as the amount of EV obtain
by a specific number of producing cells (Sahoo et al., 2011).
Likewise, pharmacokinetics and pharmacodynamics of EV-based
formulations need to be comprehensively investigated in order to
avoid any potential adverse side effects of therapeutic dose, while
ensuring efficacy.
Overall, EV biology surely represents a fascinating and
promising field to be therapeutically exploited for future cardiac
repair and regeneration strategies; yet our understandings of EV
basic mechanisms of action within the myocardial tissue, from
their biogenesis to cell targeting and specific delivery of the
informative content, need to be significantly improved.
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